Data strategy isn’t just an operational detail, it’s the foundation of a successful global launch. Companies that neglect early planning risk costly missteps, from compliance gaps to duplicated investments.
We believe data strategy is launch strategy. It’s what ensures evidence generation, regulatory alignment and commercial success in an increasingly complex global environment.
Following our session with experts from Pulse Infoframe, Global Data Support, and IOMED at Frontiers Health, our Head of Data & Analytics, Drew McCormick sat down with pharmaphorum reflecting on key topics from the discussion:
- Regulatory Patchwork: GDPR is just the start – regional variations demand strong local partnerships.
- Emerging Data Sources: Imaging, wearables, omics – new datasets promise breakthroughs, but only if fit-for-purpose.
- AI as a Tool, Not a Silver Bullet: Generative AI accelerates workflows but must fit into a coherent strategy.
- Breaking Internal Silos: Avoid costly duplication with top-down mandates and clear accountability.
Read the full pharmaphorum article and interview.
Why does this matter? Early investment in data strategy pays off with better evidence generation and smarter commercialization.
Learn more about EVERSANA’s Data & Analytics solutions.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…